Across TCGA pan-cancer cohorts, TEKT4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TEKT4 data layer compared with 23 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TEKT4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TEKT4 expression acts as an unfavorable survival marker.
LSCC and LUAD are the cancer types where TEKT4 mass-spec protein most reproducibly stratifies survival.